Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J, Chen ZS.

PLoS One. 2009 Oct 20;4(10):e7520. doi: 10.1371/journal.pone.0007520. Erratum in: PLoS One. 2009;4(11). doi: 10.1371/annotation/e57b4610-9029-48db-9d57-5cc0fa35b8ac.

2.

Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.

Kathawala RJ, Wang YJ, Ashby CR Jr, Chen ZS.

Chin J Cancer. 2014 May;33(5):223-30. doi: 10.5732/cjc.013.10122. Epub 2013 Oct 9. Review.

3.

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K.

Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220. Review.

4.

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

Jabbour E, Kantarjian H, Cortes J.

Semin Hematol. 2010 Oct;47(4):344-53. doi: 10.1053/j.seminhematol.2010.06.002. Review.

PMID:
20875551
5.

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.

Fullmer A, Kantarjian H, Cortes J, Jabbour E.

Expert Opin Pharmacother. 2010 Dec;11(18):3065-72. doi: 10.1517/14656566.2010.535655. Epub 2010 Nov 13. Review.

PMID:
21073351
6.

New strategies in controlling drug resistance.

Frame D.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):13-7. Review.

7.

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, Kéri G.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):318-25. Review.

8.

Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L.

Eur J Med Chem. 2017 Dec 15;142:271-289. doi: 10.1016/j.ejmech.2017.07.062. Epub 2017 Aug 3. Review.

PMID:
28851502
9.

Overcoming multidrug resistance in human cancer cells by natural compounds.

Nabekura T.

Toxins (Basel). 2010 Jun;2(6):1207-24. doi: 10.3390/toxins2061207. Epub 2010 May 28. Review.

10.

Targeting multidrug resistance in cancer.

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.

Nat Rev Drug Discov. 2006 Mar;5(3):219-34. Review.

PMID:
16518375
11.

Importance of ABCC1 for cancer therapy and prognosis.

Kunická T, Souček P.

Drug Metab Rev. 2014 Aug;46(3):325-42. doi: 10.3109/03602532.2014.901348. Epub 2014 Mar 26. Review.

PMID:
24670052
12.

[Genetic alterations and chemoresistance].

Akiyama S.

Gan To Kagaku Ryoho. 2005 Nov;32(12):1895-901. Review. Japanese.

PMID:
16282723
14.

Molecular mechanism of ATP-dependent solute transport by multidrug resistance-associated protein 1.

Chang XB.

Methods Mol Biol. 2010;596:223-49. doi: 10.1007/978-1-60761-416-6_11. Review.

PMID:
19949927
15.

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G, Sarkadi B.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):623-42. doi: 10.1517/17425255.2011.562892. Epub 2011 Mar 17. Review.

PMID:
21410427
16.

[Literature review and presentation of our own research results regarding the effects on bone of tyrosine kinase inhibitors imatinib and nilotinib used in the treatment of oncohematological diseases].

Kirschner G, Balla B, Kósa J, Horváth P, Kövesdi A, Lakatos G, Takács I, Nagy Z, Tóbiás B, Árvai K, Lakatos P.

Orv Hetil. 2016 Sep;157(36):1429-37. doi: 10.1556/650.2016.30525. Review. Hungarian.

PMID:
27596510
17.

Inhibitors of bacterial efflux pumps that also inhibit efflux pumps of cancer cells.

Amaral L, Spengler G, Martins A, Armada A, Handzlik J, Kiec-Kononowicz K, Molnar J.

Anticancer Res. 2012 Jul;32(7):2947-57. Review.

PMID:
22753759
18.
19.

The reversal of antineoplastic drug resistance in cancer cells by β-elemene.

Zhang GN, Ashby CR Jr, Zhang YK, Chen ZS, Guo H.

Chin J Cancer. 2015 Sep 14;34(11):488-95. doi: 10.1186/s40880-015-0048-0. Review.

20.

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.

Wang YJ, Zhang YK, Kathawala RJ, Chen ZS.

Cancers (Basel). 2014 Sep 29;6(4):1925-52. doi: 10.3390/cancers6041925. Review.

Supplemental Content

Support Center